ResearcherSichuan UniversityActive in the last 2 years
Zixing Huang
Matched on ORCID iD 0000-0001-7967-5948; OpenAlex author ID A5002433450. Sources: OpenAlex.
Their work
- Papers
- 9 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 30
2019: 1 paper · 2020: none · 2021: 2 papers · 2022: none · 2023: 1 paper · 2024: none · 2025: 3 papers · 2026: 2 papers
Papers 9
- Myosteatosis and Visceral Adiposity on Preoperative CT are Associated with Early Recurrence in Patients with Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.acra.2026.06.051↗
- Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcinoma: a multicenter, single-arm, phase II … Co-author DOI 10.1158/1078-0432.ccr-26-1824↗
- A risk score system including CT features for predicting early recurrence of resectable pancreatic ductal adenocarcinoma after radical resection: a dual-center… Co-author DOI 10.1007/s00330-025-11632-y↗
- RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line treatment for metastatic pancreatic adenocar… Co-author DOI 10.21203/rs.3.rs-7291840/v1↗
- A CT-based radiomics nomogram for the preoperative prediction of perineural invasion in pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fonc.2025.1525835↗
- Toripalimab combined with albumin-paclitaxel plus gemcitabine as first-line treatment for locally advanced or metastatic pancreatic ductal adenocarcinoma: an o… Co-author DOI 10.21203/rs.3.rs-3677396/v1↗
- A Novel Multiresolution-Statistical Texture Analysis Architecture: Radiomics-Aided Diagnosis of PDAC Based on Plain CT Images. Co-author DOI 10.1109/tmi.2020.3021254↗
- Role of imaging in evaluating the response after neoadjuvant treatment for pancreatic ductal adenocarcinoma. First author DOI 10.3748/wjg.v27.i22.3037↗
- Two-dimensional Texture Analysis Based on CT Images to Differentiate Pancreatic Lymphoma and Pancreatic Adenocarcinoma: A Preliminary Study. Co-author DOI 10.1016/j.acra.2018.07.021↗
Closest collaborators
The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Bin Song · 5 shared papers, 2019–2026 · strength 1.19
- Paper Myosteatosis and Visceral Adiposity on Preoperative CT are Associated with Early Recurrence in Patients with Resectable… DOI 10.1016/j.acra.2026.06.051↗
- Paper A CT-based radiomics nomogram for the preoperative prediction of perineural invasion in pancreatic ductal adenocarcinom… DOI 10.3389/fonc.2025.1525835↗
- Paper A risk score system including CT features for predicting early recurrence of resectable pancreatic ductal adenocarcinom… DOI 10.1007/s00330-025-11632-y↗
- Junjie Xiong · 3 shared papers, 2023–2026 · strength 0.50
- Paper Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcino… DOI 10.1158/1078-0432.ccr-26-1824↗
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
- Paper Toripalimab combined with albumin-paclitaxel plus gemcitabine as first-line treatment for locally advanced or metastati… DOI 10.21203/rs.3.rs-3677396/v1↗
- Ke Cheng · 3 shared papers, 2023–2026 · strength 0.50
- Paper Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcino… DOI 10.1158/1078-0432.ccr-26-1824↗
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
- Paper Toripalimab combined with albumin-paclitaxel plus gemcitabine as first-line treatment for locally advanced or metastati… DOI 10.21203/rs.3.rs-3677396/v1↗
- Chen Chang · 2 shared papers, 2025–2026 · strength 0.36
- Paper Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcino… DOI 10.1158/1078-0432.ccr-26-1824↗
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
- Yi Cheng · 2 shared papers, 2025–2026 · strength 0.36
- Paper Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcino… DOI 10.1158/1078-0432.ccr-26-1824↗
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
- Dan Cao · 2 shared papers, 2025–2026 · strength 0.36
- Paper Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcino… DOI 10.1158/1078-0432.ccr-26-1824↗
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
- Xiaorui Zhu · 2 shared papers, 2025–2026 · strength 0.36
- Paper Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcino… DOI 10.1158/1078-0432.ccr-26-1824↗
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
- Qingqing Leng · 2 shared papers, 2025–2026 · strength 0.36
- Paper Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcino… DOI 10.1158/1078-0432.ccr-26-1824↗
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
- Wanting Hou · 2 shared papers, 2025–2026 · strength 0.36
- Paper Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcino… DOI 10.1158/1078-0432.ccr-26-1824↗
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
- Chenyan Zhang · 2 shared papers, 2025–2026 · strength 0.36
- Paper Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcino… DOI 10.1158/1078-0432.ccr-26-1824↗
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
- Jing Zhu · 1 shared paper, 2026 · strength 0.32
- Chengjian Zhao · 2 shared papers, 2023–2025 · strength 0.31
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
- Paper Toripalimab combined with albumin-paclitaxel plus gemcitabine as first-line treatment for locally advanced or metastati… DOI 10.21203/rs.3.rs-3677396/v1↗
- Rui Wang · 2 shared papers, 2023–2025 · strength 0.31
- Paper RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line trea… DOI 10.21203/rs.3.rs-7291840/v1↗
- Paper Toripalimab combined with albumin-paclitaxel plus gemcitabine as first-line treatment for locally advanced or metastati… DOI 10.21203/rs.3.rs-3677396/v1↗
- Yan Deng · 1 shared paper, 2025 · strength 0.30
- Marc Zins · 1 shared paper, 2025 · strength 0.25
- Yan Deng · 1 shared paper, 2025 · strength 0.25
- Dan Cao · 1 shared paper, 2025 · strength 0.25
- Yun Zhang · 1 shared paper, 2021 · strength 0.22
- Yi Zhang · 1 shared paper, 2026 · strength 0.19
- Bole Tian · 1 shared paper, 2026 · strength 0.19
- Xiaoying Li · 1 shared paper, 2025 · strength 0.16
- Yi Zhang · 1 shared paper, 2025 · strength 0.16
- Huanji Xu · 1 shared paper, 2025 · strength 0.16
- Bole Tian · 1 shared paper, 2025 · strength 0.16
- Bo Chen · 1 shared paper, 2025 · strength 0.16
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.